Logo

PMN

ProMIS Neurosciences, Inc.

PMN

ProMIS Neurosciences, Inc. • NASDAQ
$6.75 ▼ -6.84% (-0.49)
Market Cap $8.82 M
52w High $39.75
52w Low $6.27
Dividend Yield 0%
P/E -0.34
Volume 82.55K
Outstanding Shares 32.69M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $11.75M ▲ $-11.58M ▼ 0% $-6 ▲ $-11.58M ▼
Q2-2025 $0 $10.185M ▲ $-10.117M ▼ 0% $-7.25 ▼ $-10.117M ▼
Q1-2025 $0 $7.46M ▲ $-7.348M ▼ 0% $-5.25 ▼ $-7.348M ▼
Q4-2024 $0 $6.002M ▲ $-238.207K ▼ 0% $-0.245 ▼ $-238.208K ▼
Q3-2024 $0 $4.435M $9.276M 0% $7.75 $9.276M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $15.432M ▲ $21.458M ▲ $12.271M ▲ $9.187M ▲
Q2-2025 $4.543M ▼ $9.509M ▼ $9.892M ▲ $-382.578K ▼
Q1-2025 $8.397M ▼ $13.647M ▼ $4.175M ▲ $9.472M ▼
Q4-2024 $13.324M ▼ $18.911M ▼ $2.423M ▼ $16.488M ▲
Q3-2024 $21.569M $24.511M $17.237M $7.273M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.58M ▼ $-10.182M ▼ $0 $21.263M ▲ $10.889M ▲ $-10.182M ▼
Q2-2025 $-10.117M ▼ $-3.854M ▲ $0 $0 $-3.854M ▲ $-3.854M ▲
Q1-2025 $-7.348M ▼ $-4.927M ▲ $0 ▲ $0 ▼ $-4.927M ▲ $-4.927M ▲
Q4-2024 $-238.207K ▼ $-8.233M ▼ $-678 ▼ $9.017K ▼ $-8.246M ▼ $-8.233M ▼
Q3-2024 $9.276M $-6.671M $0 $27.216M $20.544M $-6.671M

Five-Year Company Overview

Income Statement

Income Statement ProMIS is still a pure research-stage company with no product revenue. The income statement is dominated by R&D and overhead costs, which produce recurring operating losses. The latest year shows an accounting profit, but that appears driven by non-operational items rather than any improvement in the underlying business. In simple terms, the science is moving forward, but the business is not yet generating commercial income and remains dependent on external funding to cover its ongoing expenses.

Balance Sheet

Balance Sheet The balance sheet is very small and lean. Assets consist almost entirely of cash, with no meaningful physical assets and no debt, which reduces financial strain but also reflects the company’s early-stage scale. Equity is thin, meaning the company’s financial position is sensitive to future funding decisions, share issuances, or any setbacks. Overall, the balance sheet is clean but fragile, typical of a small clinical-stage biotech.

Cash Flow

Cash Flow Cash is being consumed by day-to-day operations, mainly research and development, with no offsetting inflows from product sales. There is essentially no investment in long-lived assets, so the main cash need is simply to fund ongoing trials and corporate costs. This means ProMIS must periodically raise money through investors or potential partners to keep its programs moving. The company’s runway and access to capital are critical risk factors to watch.

Competitive Edge

Competitive Edge ProMIS operates in one of the toughest and most crowded areas of biotech: treatments for neurodegenerative diseases like Alzheimer’s, ALS, and Parkinson’s. It competes against much larger pharmaceutical players but differentiates itself with a very focused approach to targeting toxic protein forms believed to drive disease, rather than more traditional plaque-focused strategies. Its intellectual property and specialized antibody design give it a clear scientific angle, but scale, funding, and clinical proof will determine how durable that advantage can be in the face of deep-pocketed competitors.

Innovation and R&D

Innovation and R&D Innovation is the core of ProMIS’s story. The company’s EpiSelect platform is designed to identify highly specific targets on toxic, misfolded proteins, enabling antibodies that aim to hit the “bad actors” while sparing normal proteins. The lead drug candidate for early Alzheimer’s has Fast Track status and is in an early human trial, with additional candidates for ALS, Parkinson’s, and even vaccine concepts in earlier stages. The science is ambitious and differentiated, but still early; the key uncertainty is whether this targeted approach will translate into clear clinical benefits and safety in patients.

Summary

ProMIS is a pre-revenue, clinical-stage neuroscience biotech built around a specialized platform for targeting toxic protein oligomers in diseases like Alzheimer’s. Financially, it runs ongoing operating losses, has a very small but debt-free balance sheet, and relies on external capital to fund its research. Strategically, its strength lies in a focused, IP-protected technology and a pipeline addressing very large unmet medical needs, but it faces intense competition, long development timelines, and meaningful funding and clinical-risk hurdles. Future trial data, partnering activity, and the company’s ability to sustain its cash position are likely to be the main drivers of how this story evolves.

NEWS

November 24, 2025 · 8:00 AM UTC

ProMIS Neurosciences Announces Reverse Stock Split

Read more

November 12, 2025 · 7:00 AM UTC

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Read more

November 3, 2025 · 4:05 PM UTC

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Read more

October 22, 2025 · 7:30 AM UTC

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Read more

September 3, 2025 · 7:00 AM UTC

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Read more